1049 related articles for article (PubMed ID: 16528530)
1. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
2. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
Al Safarjalani ON; Rais R; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1449-55. PubMed ID: 22373605
[TBL] [Abstract][Full Text] [Related]
3. 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.
Al Safarjalani ON; Zhou XJ; Rais RH; Shi J; Schinazi RF; Naguib FN; El Kouni MH
Cancer Chemother Pharmacol; 2005 Jun; 55(6):541-51. PubMed ID: 15729584
[TBL] [Abstract][Full Text] [Related]
4. Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine.
Ashour OM; Naguib FN; Panzica RP; Al Safarjalani ON; el Kouni MH
Biochem Pharmacol; 2000 Aug; 60(3):427-31. PubMed ID: 10856438
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil.
Naguib FN; Hao SN; el Kouni MH
Cancer Res; 1994 Oct; 54(19):5166-70. PubMed ID: 7923135
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of 5-fluoro-2'-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside.
Ashour OM; Naguib FN; Khalifa MM; Abdel-Raheem MH; Panzica RP; el Kouni MH
Cancer Res; 1995 Mar; 55(5):1092-8. PubMed ID: 7866994
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for uridine rescue regimens in chemotherapy.
Al Safarjalani ON; Zhou XJ; Naguib FN; Shi J; Schinazi RF; el Kouni MH
Cancer Chemother Pharmacol; 2001 Nov; 48(5):389-97. PubMed ID: 11761457
[TBL] [Abstract][Full Text] [Related]
8. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice.
Saif MW; von Borstel R
Cancer Chemother Pharmacol; 2006 Jul; 58(1):136-42. PubMed ID: 16187114
[TBL] [Abstract][Full Text] [Related]
9. Modulation of 5-fluorouracil in mice using uridine diphosphoglucose.
Codacci-Pisanelli G; Kralovanszky J; van der Wilt CL; Noordhuis P; Colofiore JR; Martin DS; Franchi F; Peters GJ
Clin Cancer Res; 1997 Feb; 3(2):309-15. PubMed ID: 9815688
[TBL] [Abstract][Full Text] [Related]
10. High-dose 5-fluorouracil with delayed uridine "rescue" in mice.
Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Young CW
Cancer Res; 1982 Oct; 42(10):3964-70. PubMed ID: 7104997
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for chemotherapy.
Al Safarjalani ON; Zhou XJ; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
Cancer Chemother Pharmacol; 2001 Aug; 48(2):145-50. PubMed ID: 11565561
[TBL] [Abstract][Full Text] [Related]
12. Effect of administration of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on the anti-tumor efficacy of 5-fluoro-2'-deoxyuridine against murine colon tumor C26-10.
Ashour OM; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
Biochem Pharmacol; 2000 Sep; 60(5):687-92. PubMed ID: 10927027
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice.
Tan Y; Sun X; Xu M; Tan X; Sasson A; Rashidi B; Han Q; Tan X; Wang X; An Z; Sun FX; Hoffman RM
Clin Cancer Res; 1999 Aug; 5(8):2157-63. PubMed ID: 10473100
[TBL] [Abstract][Full Text] [Related]
14. Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools.
Pizzorno G; Wiegand RA; Lentz SK; Handschumacher RE
Cancer Res; 1992 Apr; 52(7):1660-5. PubMed ID: 1551097
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Emura T; Suzuki N; Fujioka A; Ohshimo H; Fukushima M
Int J Oncol; 2005 Aug; 27(2):449-55. PubMed ID: 16010427
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
17. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
18. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.
Klubes P; Cerna I
Cancer Res; 1983 Jul; 43(7):3182-6. PubMed ID: 6850628
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]